The Visalli laboratory uses human and animal herpesviruses as model organisms to understand the mechanism of viral genome (DNA) processing and packaging (i.e. encapsidation). He is interested in the function of proteins that form the encapsidation machinery (i.e. the terminase and portal proteins), portal structure, and the identification of antivirals that inhibit DNA encapsidation. Dr. Visalli was the lead scientist involved in the identification of novel encapsidation inhibitors and through studies concerning the highly conserved function and structure of portal proteins, seeks to define their  mechanism of action. These studies may lead to new broad-spectrum therapeutic options to treat herpesvirus infections. Recently, Dr. Visalli’s laboratory started a new research program on the role of herpes simplex virus proteins in Alzheimer’s Disease. There is growing evidence that HSV-1, found latent in more than two-thirds of the world’s population, may contribute to AD. Exciting preliminary studies have identified a novel, specific HSV-1 protein that interacts with the amyloid precursor protein (APP) and may influence the production of beta-amyloid.

Dr. Robert Visalli is a Professor of Microbiology and Associate Dean of Biomedical Research in the Department of Biomedical Sciences at Mercer University School of Medicine-Savannah. He is a candidate for the Kummer Endowed Department Chair of Biological Sciences